NCT07179536 Time to Ambulation After ProGlide Closure
| NCT ID | NCT07179536 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
| Condition | Femoral Access Site Closure |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-10-01 |
| Primary Completion | 2026-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2025-10-01 with a primary completion date of 2026-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Transradial access has become the standard for coronary procedures due to fewer vascular complications and shorter bed rest, yet transfemoral access remains essential for complex peripheral interventions requiring larger sheaths and stronger support. Vascular closure devices (VCDs), particularly suture-mediated devices such as ProGlide, have improved femoral access by reducing hemostasis time, ambulation delay, and patient discomfort. Although early ambulation after ProGlide closure has been reported, current practice varies widely, and the relationship between ambulation timing and vascular complications remains unclear. This trial aims to evaluate the effect of different ambulation times after ProGlide closure in transfemoral peripheral angiography or intervention, with the goal of identifying the optimal time to ambulation that balances safety and efficiency.
Eligibility Criteria
Inclusion Criteria: * Scheduled for peripheral angiography or endovascular intervention via transfemoral access. * Femoral artery puncture site located at the common femoral artery. * Use of 6-8F vascular sheath. * Hemostasis achieved with 6F ProGlide closure device (defined as no active bleeding, no hematoma formation, and no ischemia of the punctured limb after closure). * Preoperative ankle-brachial index (ABI) \> 0.9 on both sides. * Conscious, cooperative, and with normal lower limb mobility. Exclusion Criteria: * Undergoing carotid artery intervention. * Femoral artery diameter \< 5 mm, or effective lumen \< 5 mm due to plaque burden. * History of vascular complications at the puncture site. * Abnormal cardiopulmonary function. * Intraoperative platelet count \< 80 × 10⁹/L, or use of thrombolytic agents. * Cognitive impairment, uncooperative, or limited lower limb mobility.
Contact & Investigator
Hui Dong, MD
PRINCIPAL INVESTIGATOR
Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College
Frequently Asked Questions
Who can join the NCT07179536 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Femoral Access Site Closure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07179536 currently recruiting?
Yes, NCT07179536 is actively recruiting participants. Contact the research team at donghui666@sina.com for enrollment information.
Where is the NCT07179536 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07179536 clinical trial?
NCT07179536 is sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital. The principal investigator is Hui Dong, MD at Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College. The trial plans to enroll 300 participants.